Introduction
Cardiovascular disease (CVD) is a major cause of mortality worldwide. Even, the relative rate of death decreases, it was estimated that one of every three deaths caused by CVD (1) . Coronary artery disease (CAD) usually caused by atherosclerosis involves an ongoing inflammatory response in the coronary arterial vessel wall (2, 3) . Inflammation is controlled by several hormones and cytokines. Adipose tissue secretes a variety of adipokines, including leptin, adiponectin, visfatin, resistin and omentin, and it is accepted as an endocrine organ because of effecting several organs and systems in metabolism (4) (5) (6) (7) . Omentin is a recently identified adipokine that is selectively expressed in visceral adipose tissue (8, 9) . Omentin was identified from a cDNA library from, visceral omental adipose tissue by Yang et al. (10) in 2003. Recent studies have shown that omentin-1 levels are negatively correlated with acute coronary syndrome, stable angina pectoris (11) . Plasma levels of omentin correlated negatively with systolic blood pressure, hemoglobin A1C, body mass index and total cholesterol levels and positively with High Density Lipoprotein (HDL) cholesterol (12) . These data indicate that low levels of omentin are associated with CAD and omentin may serve as a novel biomarker for CAD. However; significance of missense polymorphism (Val109Asp) in the human omentin gene in connection with CAD has not been studied. Therefore the aim of this study was to investigate the relationship between omentin Val109Asp polymorphism and CAD.
Methods

Study design and patients
This is an observational study on genetic association. 157 consecutive patients who had undergone coronary angiography in Düzce University School of Medicine Cardiology Clinic between March 2011 and December 2011 were included in the study. Coronary artery disease was defined as >50% stenosis in at least one major coronary artery (LMCA, LAD, CX or RCA) in coronary angiography (13) . Indications of coronary angiography were positive stress test for ischemia, typical and atypical chest pain in patients with a high risk score for CAD. Exclusion criteria were the presence of malignancy or any acute or chronic inflammatory diseases. The study was approved by the Clinical Research Ethics Committee of Düzce University. An informed consent was obtained from every participant.
Genotyping omentin Val109Asp polymorphism
Genotyping omentin Val109Asp SNP was determined by PCRbased RFLP (restriction fragment length polymorphism) assay. For this purpose, venous blood was collected from each subject into vacutainer tubes containing EDTA, and genomic DNA was extracted using PureLink TM Genomic DNA Isolation kit (Invitrogen, Carlsbad, California, USA). A 471 bp DNA fragment was amplified using the upstream primer 5'-GAGCCTTTAGGCCATGTCTCT-3' and the downstream primer 5'-CTCTCCTTCTTCTCCAGCCCAT-3' in Bioneer My GenieTM 96 Gradient Thermal Block (Daejeon, Korea). The PCR cycling conditions were 5 min at 94 o C followed by 35 cycles of 1 min at 94 o C, 1 min at 58 o C, and 1 min at 72 o C, with a final step at 72 o C for 10 min. The PCR product subjected to digestion at 37 o C by Xmil (AccI) restriction enzyme (Fermantas). After digestion, the products were separated by agarose gel, stained with ethidium bromide. As a results of agarose gel electrophoresis, Val/Val (GTC/GTC) homozygotes show two bands (274bp, 197bp), Val/Asp (GTC/GAC) heterozygotes show three bands (471 bp, 274 bp, 197 bp), and Asp/Asp (GTC/GTC) homozygotes show single band (471 bp) (14) .
Statistical analysis
Statistical Package for Social Sciences software (SPSS 12, Chicago, IL, USA) was used for analysis. Descriptive parameters were shown as mean±standard deviation or in percentages. Kolmogorov-Smirnov test was used to test normal distribution. Kruskal-Wallis test was used to compare abnormally distributed data among genotype groups. Independent samples t-tests and Pearson's chi-square tests were used to analyze the differences in means and proportions between groups. Abnormally distributed variables were compared using the Mann-Whitney U test. Odds ratios and their confidence intervals based on genotype frequency were measured by StatCalc of EpiInfo software. Comparisons between groups were tested with ANOVA. Post-hoc analysis was done with Scheffe test. A p value below 0.05 was considered significant.
Results
Subject characteristics
Seventy-five patients (48 men and 27 women with a mean age of 64) were diagnosed as having CAD. The rest of the patients (45 men and 37 women with a mean age of 57) had normal vessels or non-significant stenosis served as the control group.
Comparison of demographic and clinical characteristics of the study groups were shown in Table 1 Table 2 .
Clinical characteristics according to genotype groups
The clinical and metabolic characteristics of all study population were further analyzed according to the genotype groups. None of the variables were significantly different except there was a significant female predominance in the Val/Val genotype group (Table 3) .
Discussion
The present study showed that there was no significant difference between CAD patients and control subjects regarding omentin Val109Asp polymorphism. However, a 2.5 fold increase in Val/Val (homozygous mutant) genotype was detected in patients with CAD.
The recent researches has been showed that the adipose tissue is not only a repository for lipids but also secretes several hormon like protein called adipokines including leptin, adiponectin, resistin, visfatin and omentin. So, adipose tissue is recognized as an endocrine organ due to the involvement of the adipokines in several vital pyhsiological and pahtological processes. On the other hand, the rate of obesity is increasing rapidly in western world like in our country. Therefore, the researchers have focused on the relationship between CAD and adipose tissue with its products. The adipokines with inflammatory characteristics have become the potential target to be biomarker for CAD (15) (16) (17) . Up to date, several studies have been conducted, and the association of CAD and leptin (18) , resistin (19) , adiponectin (20) , and visfatin (21) have been reported, but this association remain poorly understood (22) .
In this study we investigated that the relationship between CAD and omentin, the last characterized adipokine. Even significantly difference was not found between CAD patients and control subjects regarding omentin Val109Asp polymorphism, Val/Val (homozygous mutant) genotype was found 2.5 fold times more in patients with CAD than control group (OR=3.46). Omentin is expressed in visceral adipose tissue and it has anti-inflammatory effects (23) . The omentin gene is located in the 1q22-q23 chromosomal region. It has been linked to type 2 diabetes in several populations (8, 9) , suggesting that omentin may be a candidate gene for type 2 diabetes susceptibility in humans. The relationship between circulating omentin-1 with cardiovascular health were investigated in several clinical studies. Moreno-Navarrete et al. (24) demonstrated that omentin was independently associated with endothelial dysfunction after controlling for adiposity, age, and inflammation in subjects with impaired glucose tolerance. A negative correlation of omentin was also shown with increased carotid-intima media thickness in patients with metabolic syndrome (25) . De Souza et al. (26) showed that omentin gene expression was decreased with obesity and decreased omentin levels were associated with increasing obesity and insulin resistance. Furthermore, serum omentin-1 levels were shown to be inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome (27) . This data showed that there may be a putative role of human omentin gene missense variation in patients with cardiovascular disease. However, Schäffler et al. (14) could not show any significant association between genotype subgroups and anthropometric or laboratory parameters in patients with type 2 DM. We have further analyzed omentin gene polymorphism in CAD and could not show any significant difference. However, there was a 2.5 fold increase in Val/Val homozygous mutant in patients with CAD indicating a larger study in different populations.
Study limitations
A possible limitation of the study was the small number of population. Further studies with larger study population are mandatory. In addition other polymorphisms in omentin gene also should be analyzed.
Conclusion
It can be concluded from our data that Val/Val genotype increases the tendency for CAD however there was no signifi- 
